Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Peptide containing doai
Reexamination Certificate
2008-01-01
2008-01-01
Rawlings, Stephen L. (Department: 1643)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Peptide containing doai
C530S324000, C530S350000, C435S375000, C514S012200
Reexamination Certificate
active
10076905
ABSTRACT:
The present invention relates to novel therapies for cancer and, in particular, to therapies that are particularly suited to tumor cells resistant to other types of therapies such as radiation, chemotherapy, or combinations of both approaches. The invention provides methods for identifying and implementing strategies to inhibit a transcription factor which, in combination with other factors, renders the cells resistant and inhibits apopotosis of the cells. The invention provides an inhibitory ATF2 N-terminal fragment, specifically a fragment corresponding to amino acid residues 50-100 of ATF2 (termed peptide II). The invention provides methods for inhibiting tumor cell growth with such peptides.
REFERENCES:
patent: 5736381 (1998-04-01), Davis et al.
patent: 6335178 (2002-01-01), Weiner et al.
patent: 6579856 (2003-06-01), Mercola
Duyndam MCA, et al. Oncogene. 1999; 18: 2311-21.
Gura T. Science. 1997; 278: 1041-42.
van Dam H, et al. EMBO J. Apr. 18, 1995; 14 (8): 1798-811.
Crawford et al. (Annu. Rev. Genomics Hum. Genet. 2005; 6: 287-312).
GenBank™ Accession No. AAH26175 (Version AAH26175.1; GI:20072897).
GenBank™ Accession No. BC026175 (Version BC026175.1; GI: 20072896).
Bailey et al. (J. Mol. Endocrinol. Feb. 2005; 34 (1): 19-35).
Jobling et al. (Plasmid. 1997; 38: 158-173).
Nilsson et al. (Nucleic Acid Res. 1985; 13 (4): 1151-1162).
Livingstone et al. (EMBO J. 1995; 14 (8): 1785-1797).
Abdel-Hafiz et al. (Mol. Endocrinol. Dec. 1992; 6 (12): 2079-2089).
Duyndam et al. (Oncogene. 1999; 18: 2311-2321).
Bhoumik et al. (Cancer Res. Nov. 15, 2004; 64: 8222-8230).
Bhoumik et al. (Proc. Natl. Acad. Sci USA. Mar. 23, 2004; 101 (12): 4222-4227).
Mi et al. (Mol. Ther. Oct. 2000; 2 (4): 339-347).
Ahmed et al. (J. Immunol. 2006; 177: 315-321).
Bhoumik et al., Clin. Cancer Res. 2001; 7(2):331-42.
Ivanov, V.N., and Ronai, Z., Oncogene 2000; 19: 3003-3012.
Ivanov, V.N. et al., Oncogene 2000; 19: 933-942.
Yang, Y.-M et al., Oncogene, 12 :2223-2233, 1996.
Ronai, Z. et al, Oncogene 1998; 16: 523-531.
Ivanov, V.N. et al., J. Biol. Chem. 1999; 274:14079-14089.
Gupta, S. et al., Science 1995; 267: 389-393.
Fuchs, S.Y. and Ronai, Z., Mol. Cell Biol. 1999; 19: 3289-3298.
Georgopoulos, K. et al., Mol. Cell. Biol.1992; 12: 747-757.
Huguier S. et al., Mol. Cell Biol. 1988; 18:7020-7029.
Bhoumik, A. et al., ATF-2 derived peptide sensitizes melanoma to treatment and inhibits in vivo growth and metastasis through altered ATF-2 and c-Jun transcriptional activities. (manuscript submitted toCancer Cell).
Fritz et al., Journal of Biological Chemistry 1997; 272: 30637-30644 (abstract only).
Anindita Bhoumik et al., “An ATF2-Derived Peptide Sensitizes Melanomas to Apoptosis and Inhibits Their Growth and Metastasis,” Sep. 2002, vol. 110, No. 5, pp. 643-650.
Anindita Bhoumik et al., “Transcriptional Switch By Activating Transcription Factor 2-Derived Peptide Sensitizes Melanoma Cells to Apoptosis and Inhibits Their Tumorigenicity,” Mar. 23, 2004, vol. 101, No. 12, pp. 4222-4227.
Cho et al., TIP49b, a Regulator of Activating Transcription Factor 2 Response to Stress and DNA damage. Mol. Cell. Biol. 2001. 21:8398-8413.
Buschmann et al., Amino-terminal-derived JNK Fragment Alters Expression and Activity of c-Jun, ATF2, and p56 and Increases H202-induced Cell Death, J. Biol. Chem. 2000; 278: 16590-96.
Darby & Darby P.C.
Mount Sinai School of Medicine of New York University
Rawlings Stephen L.
LandOfFree
Inhibition of ATF2 activity to treat cancer does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Inhibition of ATF2 activity to treat cancer, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Inhibition of ATF2 activity to treat cancer will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3920706